Figure 8 | Scientific Reports

Figure 8

From: Development of a Phage Display Panning Strategy Utilizing Crude Antigens: Isolation of MERS-CoV Nucleoprotein human antibodies

Figure 8

The production of antibody fragments and their antigen binding ELISA assay against rMERS-NP(His6) and cross-reactivity assay against other His6-tagged protein. (a) Western blotting analysis of rA4scFv, rG12scFv and rC8scFv using streptavidin-HRP was performed. M indicates Opti-Protein XL Marker prestained protein ladder (Abm Inc.); lane 1, purified rA4scFv; lane 2, purified rG12scFv; lane 3, purified rC8scFv; lane C, positive control. (b–e) The antibody fragments were subjected to antigen binding ELISA assay against a serial dilution of rMERS-NP(His6) at various concentrations. The absorbance of each set of samples after normalizing with background values are presented as mean ± s.d. (n = 3) in the line graphs, (b) rA4scFv, (c) rG12scFv and (d) rC8scFv. (e) is the absorbance of the control set during the ELISA assay. (f) Cross-reactivity ELISA assay of antibody fragments against other His6-tagged protein was also performed. The control antigen used is 10 μg of rGFP(His6). The absorbance for all sample sets were collected in triplicates and presented as mean ± s.d. (n = 3) in the bar graph.

Back to article page